

Johnson & Johnson to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting and the Janssen Oncology Strategy and Portfolio

Press Contacts:

Brian Kenney
(215) 620-0111

Suzanne Frost
(416) 317-0304

Investor Contacts:

Jessica Moore
(732) 524-2955

Raychel Kruper
(732) 524-6164

New Brunswick, NJ (May 24, 2022) -- The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) will participate in a pre-recorded fireside chat webcast hosted by Cantor Fitzgerald focused on clinical data being presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The webcast is intended for investors and other interested parties, and will be available the week of May 30, 2022.

The webcast will feature Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC, who will highlight key clinical data from across the portfolio and pipeline, including CARVYKT[™] (ciltacabtagene autoleucl), RYBREVANT[®] (amivantamab-vmjw), IMBRUVICA[®] (ibrutinib), BALVERSA[®] (erdafitinib) and teclistamab. Dr. Lebowitz will also discuss the company's scientific and open innovation strategies in oncology across the key disease areas of focus (e.g., hematologic malignancies, prostate cancer, lung cancer, bladder cancer, etc.) and Johnson & Johnson's future in oncology.

The webcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations." The webcast duration is approximately 30 minutes and will be available through the end of July.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development. The reader is cautioned not to

rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

###